西南证券发布药明康德研报：CXO龙头业绩亮眼，小分子DM双位数增速、TIDES增长强劲

Group 1 - The core viewpoint of the report highlights the impressive year-on-year growth in revenue and profit for WuXi AppTec in Q2 [2] - The revenue growth of small molecule drug development (DM) exceeded expectations, while TIDES continued to show strong growth [2] - The laboratory business remained stable, although competition in the clinical CRO market continues to be a factor that needs to be addressed [2]